[A case of postoperative recurrent lung cancer with long survival due to gefitinib efficacy].
A 70-year-old woman underwent a right middle lobectomy and partial resection of right upper lobe for lung cancer. The pathological findings were well-differentiated adenocarcinoma, pT2N0M0, Stage IB. About 6 years after the operation, the serum CEA level increased and chest CT revealed right pleural dissemination and right pleural effusion. We diagnosed it as a recurrence of the lung cancer. Although we recommended chemotherapy, she hesitated and went without treatment for about 1 year. Then, 1 month after beginning gefitinib, her serum CEA level normalized and the recurrent lesion disappeared on chest CT. She has since a shown complete response with gefitinib for over 4 years and is still alive.
Okagawa
Takehiko
T
Dept. of Chest Surgery, Aichi Cancer Center Aichi Hospital.
Uchida
Tatsuo
T
Suyama
Motokazu
M
D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002272:Carcinoembryonic Antigen / Q000097:blood; D004334:Drug Administration Schedule; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D011799:Quinazolines / Q000627:therapeutic use*; D017741:Survivors
D000970:Antineoplastic Agents; D002272:Carcinoembryonic Antigen; D011799:Quinazolines; D000077156:Gefitinib